AB Science SA Announces that European Medicines Agency Accepts Marketing Application for Masitinib in the Treatment of Gleevec resistant Gastro-Intestinal Stromal Tumor

AB Science SA announced that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for masitinib in the treatment of patients with Gleevec-resistant gastro-intestinal stromal tumors (GIST). Filing for the Marketing Authorization of masitinib in GIST resistant to Gleevec was accepted by EMA on the basis of results from a phase II study that showed masitinib to improve overall survival in patients with Gleevec-resistant GIST as compared with Sutent (sunitinib) from Pfizer, which is currently the standard of care for second-line treatment of GIST.